Christina Magdy Danial, MD
Dermatology · Danville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Danial’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A143746 · Current
Licensed to practise in California · since 2016 · expires 2027-08-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$124,496
Medicare paid this office $124,496 for 397 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 232 | $23,680 | $77 |
| Return visit (30+ min) | 131 | $18,428 | $110 |
| Biopsy of related skin growth, first growth | 120 | $12,936 | $90 |
| Destruction of skin growth, 1-14 growths | 89 | $10,809 | $107 |
| Destruction of precancer skin growth, 1 growth | 136 | $7,852 | $47 |
See all 13 services
| Short return visit (20+ min) | 232 | $23,680 | $77 |
| Return visit (30+ min) | 131 | $18,428 | $110 |
| Biopsy of related skin growth, first growth | 120 | $12,936 | $90 |
| Destruction of skin growth, 1-14 growths | 89 | $10,809 | $107 |
| Destruction of precancer skin growth, 1 growth | 136 | $7,852 | $47 |
| New patient visit (30+ min) | 53 | $5,106 | $96 |
| Biopsy of related skin growth, each additional growth | 61 | $5,066 | $52 |
| Destruction of precancer skin growth, 2-14 growths | 105 | $4,376 | $7 |
| New patient visit (45+ min) | 28 | $4,103 | $147 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 13 | $3,728 | $287 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $3,425 | $171 |
| Punch biopsy, first skin growth | 22 | $2,864 | $125 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $363 | $23 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 499 | More than 87% of doctors who do this |
| Removal or shaving of skin growth | 21 | More than 71% of doctors who do this |
| Skin biopsy | 268 | More than 89% of doctors who do this |
Who their Medicare patients are
397 Original Medicare patients in 2024. Average age 74 · Under 65 3% · 85 and older 9% · Women 62% · Also on Medicaid 7% · Health risk score 0.86. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 58% · Coronary heart disease 22% · Diabetes 15% · Chronic kidney disease 15% · Atrial fibrillation 14% · Cancer 13% · Depression 13% · Heart failure 11% · COPD 5% · Dementia 3% · Stroke 3%.
The office billed $469,932, Medicare allowed $168,830 and paid $124,496; for 2,091 services of 50 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 397 | 2,091 | 74 | 0.86 | $469,932 | $124,496 |
| 2023 | 354 | 2,015 | 74 | 0.88 | $481,879 | $132,367 |
| 2022 | 330 | 1,890 | 73 | 0.87 | $403,790 | $114,742 |
| 2021 | 299 | 1,780 | 73 | 0.82 | $376,331 | $109,381 |
| 2020 | 172 | 778 | 73 | 0.91 | $159,196 | $42,713 |
| 2019 | 72 | 286 | 71 | 0.74 | $55,140 | $15,715 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 149 | $21,258 | $107 |
| Short return visit (20+ min) | 196 | $19,728 | $74 |
| Biopsy of related skin growth, first growth | 128 | $13,488 | $88 |
| Destruction of skin growth, 1-14 growths | 99 | $12,578 | $111 |
| Destruction of precancer skin growth, 1 growth | 127 | $7,360 | $46 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 21 | $6,447 | $280 |
| Biopsy of related skin growth, each additional growth | 69 | $6,239 | $51 |
| Destruction of precancer skin growth, 15 or more growths | 18 | $4,284 | $165 |
| New patient visit (45+ min) | 30 | $3,855 | $129 |
| Destruction of precancer skin growth, 2-14 growths | 98 | $3,837 | $7 |
| New patient visit (30+ min) | 34 | $2,697 | $79 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 15 | $2,499 | $125 |
| Punch biopsy, first skin growth | 19 | $2,452 | $123 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $506 | $24 |
2022: 15 services
| Short return visit (20+ min) | 167 | $18,098 | $77 |
| Return visit (30+ min) | 116 | $16,069 | $110 |
| Biopsy of related skin growth, first growth | 131 | $15,430 | $91 |
| Destruction of skin growth, 1-14 growths | 65 | $7,588 | $104 |
| Biopsy of related skin growth, each additional growth | 61 | $7,132 | $51 |
| Destruction of precancer skin growth, 1 growth | 106 | $5,939 | $44 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 19 | $5,317 | $280 |
| Destruction of precancer skin growth, 15 or more growths | 21 | $4,737 | $169 |
| New patient visit (30+ min) | 48 | $4,130 | $86 |
| Destruction of precancer skin growth, 2-14 growths | 80 | $3,715 | $7 |
| New patient visit (45+ min) | 28 | $3,433 | $123 |
| Punch biopsy, first skin growth | 23 | $2,973 | $124 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 11 | $1,955 | $122 |
| Application of ultraviolet light to skin | 13 | $1,710 | $23 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $401 | $24 |
2021: 14 services
| Return visit (30+ min) | 97 | $13,364 | $108 |
| Short return visit (20+ min) | 129 | $13,210 | $77 |
| Biopsy of related skin growth, first growth | 107 | $12,753 | $94 |
| Destruction of skin growth, 1-14 growths | 83 | $11,110 | $110 |
| New patient visit (30+ min) | 66 | $6,042 | $92 |
| Biopsy of related skin growth, each additional growth | 57 | $5,429 | $52 |
| Destruction of precancer skin growth, 1 growth | 101 | $5,403 | $43 |
| Destruction of precancer skin growth, 15 or more growths | 18 | $4,061 | $162 |
| New patient visit (45+ min) | 27 | $3,807 | $141 |
| Destruction of precancer skin growth, 2-14 growths | 85 | $3,756 | $7 |
| Punch biopsy, first skin growth | 22 | $3,209 | $128 |
| New patient visit (15+ min) | 29 | $1,512 | $52 |
| Application of ultraviolet light to skin | 11 | $674 | $24 |
| Short return visit | 11 | $543 | $49 |
2020: 10 services
| Biopsy of related skin growth, first growth | 55 | $5,610 | $88 |
| Short return visit (20+ min) | 69 | $4,897 | $60 |
| New patient visit (30+ min) | 56 | $4,779 | $85 |
| Return visit (30+ min) | 36 | $4,732 | $97 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $2,947 | $155 |
| Destruction of skin growth, 1-14 growths | 24 | $2,678 | $103 |
| Destruction of precancer skin growth, 1 growth | 46 | $2,365 | $41 |
| Biopsy of related skin growth, each additional growth | 24 | $1,927 | $51 |
| New patient visit (15+ min) | 31 | $1,739 | $56 |
| Destruction of precancer skin growth, 2-14 growths | 40 | $1,423 | $6 |
2019: 5 services
| New patient visit (30+ min) | 34 | $3,319 | $98 |
| Short return visit (20+ min) | 25 | $1,949 | $67 |
| Biopsy of related skin growth, first growth | 20 | $1,717 | $82 |
| Destruction of precancer skin growth, 1 growth | 25 | $1,384 | $53 |
| Destruction of precancer skin growth, 2-14 growths | 22 | $561 | $5 |
Drugs they prescribed that Part D paid
$145,769
Pharmacies billed $145,769 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 482) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
451 generic and 31 brand-name prescriptions · $145,769 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Clobetasol Propionate | 55 | $3,520 | $64 |
| Fluorouracil | 37 | $3,198 | $86 |
| Ketoconazole | 78 | $1,435 | $18 |
| Tacrolimus | 16 | $994 | $62 |
| Fluocinonide | 23 | $986 | $43 |
See all 12 drugs
| Clobetasol Propionate | 55 | $3,520 | $64 |
| Fluorouracil | 37 | $3,198 | $86 |
| Ketoconazole | 78 | $1,435 | $18 |
| Tacrolimus | 16 | $994 | $62 |
| Fluocinonide | 23 | $986 | $43 |
| Tretinoin | 12 | $619 | $52 |
| Doxycycline Hyclate | 14 | $431 | $31 |
| Triamcinolone Acetonide | 71 | $392 | $6 |
| Minoxidil | 15 | $292 | $19 |
| Mometasone Furoate | 17 | $235 | $14 |
| Hydrocortisone | 39 | $186 | $5 |
| Mupirocin | 15 | $126 | $8 |
Year by year
| 2024 | 482 | 197 | 0% (0) | 6% | $145,769 |
| 2023 | 485 | 179 | 0% (0) | 7% | $43,249 |
| 2022 | 373 | 162 | 0% (0) | 4% | $17,615 |
| 2021 | 333 | 127 | 0% (0) | 5% | $15,083 |
| 2020 | 195 | 77 | 0% (0) | 10% | $10,670 |
| 2019 | 73 | 37 | 0% (0) | None | $21,906 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Jublia | 12 | $10,039 | $837 |
| Fluorouracil | 36 | $3,360 | $93 |
| Clobetasol Propionate | 40 | $3,017 | $75 |
| Ketoconazole | 74 | $1,313 | $18 |
| Metronidazole | 20 | $1,221 | $61 |
| Doxycycline Hyclate | 20 | $1,046 | $52 |
| Triamcinolone Acetonide | 58 | $720 | $12 |
| Clindamycin Phosphate | 11 | $675 | $61 |
| Fluocinonide | 14 | $525 | $37 |
| Hydrocortisone | 61 | $320 | $5 |
| Mometasone Furoate | 13 | $271 | $21 |
| Mupirocin | 23 | $232 | $10 |
| Cephalexin | 12 | $52 | $4 |
2022: 11 drugs
| Clobetasol Propionate | 25 | $2,390 | $96 |
| Fluorouracil | 23 | $2,367 | $103 |
| Ketoconazole | 43 | $1,260 | $29 |
| Desonide | 11 | $1,158 | $105 |
| Metronidazole | 18 | $1,109 | $62 |
| Fluocinonide | 14 | $915 | $65 |
| Clindamycin Phosphate | 15 | $871 | $58 |
| Triamcinolone Acetonide | 69 | $654 | $9 |
| Mometasone Furoate | 22 | $475 | $22 |
| Mupirocin | 18 | $168 | $9 |
| Hydrocortisone | 31 | $162 | $5 |
2021: 11 drugs
| Clobetasol Propionate | 17 | $2,168 | $128 |
| Fluorouracil | 19 | $1,520 | $80 |
| Ketoconazole | 41 | $1,158 | $28 |
| Metronidazole | 12 | $997 | $83 |
| Fluocinonide | 17 | $916 | $54 |
| Clindamycin Phosphate | 21 | $643 | $31 |
| Triamcinolone Acetonide | 52 | $430 | $8 |
| Mometasone Furoate | 16 | $321 | $20 |
| Hydrocortisone | 36 | $204 | $6 |
| Mupirocin | 14 | $126 | $9 |
| Cephalexin | 11 | $59 | $5 |
2020: 5 drugs
| Clobetasol Propionate | 13 | $905 | $70 |
| Ketoconazole | 21 | $573 | $27 |
| Triamcinolone Acetonide | 38 | $303 | $8 |
| Doxycycline Hyclate | 11 | $212 | $19 |
| Hydrocortisone | 15 | $71 | $5 |
2019: 1 drug
| Triamcinolone Acetonide | 13 | $183 | $14 |
Money from drug and device companies
$875 in 2025
| 2025 | 14 | 42 | None | $875 |
| 2024 | 7 | 24 | None | $529 |
| 2023 | 2 | 3 | None | $68 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Rinvoq | $219 | 11 payments
|
| Galderma Laboratories L.P. | Nemluvio | $99 | 4 payments
|
| Lilly USA | Taltz | $96 | 9 payments
|
| Regeneron Healthcare Solutions | Dupixent | $91 | 3 payments
|
| Genzyme | Dupixent | $82 | 2 payments
|
| Janssen Biotech | Tremfya | $81 | 3 payments
|
See all 42 published payments
| Abbvie | Meals · 2025-12-20 | Rinvoq | $22 |
| Abbvie | Meals · 2025-12-19 | Skyrizi | $8 |
| LEO Pharma | Meals · 2025-12-05 | Anzupgo | $22 |
| Galderma Laboratories L.P. | Meals · 2025-12-02 | Nemluvio | $27 |
| Arcutis Biotherapeutics | Meals · 2025-11-24 | Zoryve | $16 |
| Abbvie | Meals · 2025-11-21 | Rinvoq | $28 |
| Novartis Pharmaceuticals | Meals · 2025-10-30 | Rhapsido | $32 |
| Galderma Laboratories L.P. | Meals · 2025-10-18 | Nemluvio | $20 |
| Lilly USA | Meals · 2025-10-09 | Taltz | $9 |
| Abbvie | Meals · 2025-10-03 | Rinvoq | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-10-02 | Dupixent | $29 |
| Arcutis Biotherapeutics | Meals · 2025-09-29 | Zoryve | $21 |
| Organon | Meals · 2025-09-22 | None | $14 |
| Lilly USA | Meals · 2025-09-11 | Taltz | $7 |
| Lilly USA | Meals · 2025-09-11 | Taltz | $5 |
| Janssen Biotech | Meals · 2025-09-08 | Tremfya | $26 |
| Pfizer | Meals · 2025-09-05 | Cibinqo | $24 |
| Genzyme | Meals · 2025-08-28 | Dupixent | $35 |
| Abbvie | Meals · 2025-08-23 | Skyrizi | $15 |
| Lilly USA | Meals · 2025-08-21 | Ebglyss | $29 |
| Lilly USA | Meals · 2025-08-21 | Ebglyss | $4 |
| Regeneron Healthcare Solutions | Meals · 2025-08-08 | Dupixent | $32 |
| Pfizer | Meals · 2025-07-31 | Cibinqo | $14 |
| Amgen | Meals · 2025-07-24 | Otezla | $20 |
| Galderma Laboratories L.P. | Meals · 2025-07-08 | Nemluvio | $14 |
| Abbvie | Meals · 2025-06-24 | Skyrizi | $10 |
| Lilly USA | Meals · 2025-06-20 | Taltz | $12 |
| Abbvie | Meals · 2025-06-10 | Rinvoq | $12 |
| Genzyme | Meals · 2025-06-06 | Dupixent | $47 |
| Janssen Biotech | Meals · 2025-06-05 | Tremfya | $18 |
| Lilly USA | Meals · 2025-05-29 | Ebglyss | $11 |
| Lilly USA | Meals · 2025-05-16 | Taltz | $10 |
| Abbvie | Meals · 2025-05-16 | Skyrizi | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-27 | Sotyktu | $26 |
| Galderma Laboratories L.P. | Meals · 2025-03-21 | Nemluvio | $38 |
| Lilly USA | Meals · 2025-02-13 | Taltz | $10 |
| Regeneron Healthcare Solutions | Meals · 2025-02-07 | Dupixent | $30 |
| Abbvie | Meals · 2025-01-31 | Skyrizi | $15 |
| Abbvie | Meals · 2025-01-31 | Rinvoq | $33 |
| Incyte | Meals · 2025-01-25 | Opzelura | $18 |
| Abbvie | Meals · 2025-01-24 | Rinvoq | $33 |
| Janssen Biotech | Meals · 2025-01-16 | Tremfya | $38 |
See earlier years (2024, 2023)
2024: $529
| Lilly USA | Taltz | $151 | 9 payments
|
| Genzyme | Dupixent | $105 | 3 payments
|
| Janssen Biotech | Tremfya | $102 | 3 payments
|
| Abbvie | Skyrizi | $67 | 4 payments
|
| Incyte | Opzelura | $47 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $43 | 2 payments
|
| Galderma Laboratories L.P. | None | $14 | 1 payment
|
2023: $68
| Novartis Pharmaceuticals | Cosentyx | $54 | 2 payments
|
| Incyte | Opzelura | $13 | 1 payment
|
Professional record
- NPI
- 1295122398
- Licence
- CA A143746California A143746: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2015-04-16
- NPI last updated
- 2022-02-22
- NPI record certified
- 2022-02-22
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4000 Dublin Blvd, Dublin, CA, 94568 · 751 S Bascom Ave, San Jose, CA, 95128